In one paragraphArticle in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Sotirios RoussosDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0003-2347-0817 Konstantinos Protopapas4th Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Chaidari, Greece.ORCID 0000-0001-5404-746X Elpida Mastrogianni1st Department of Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0003-3081-9415 Charisis Totsikas5th Department of Internal Medicine-Infectious Diseases Unit, Evangelismos General Hospital, 10676 Athens, Greece.ORCID 0009-0008-7179-2742 Charalampos D Moschopoulos4th Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Chaidari, Greece.ORCID 0000-0001-9954-7409 Stylianos Bourmpoutelis1st Department of Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Panagiota RestaDepartment of Biomedical Sciences, University of West Attica, 12243 Athens, Greece.
Kassandra ProcterDepartment of Biomedical Sciences, University of West Attica, 12243 Athens, Greece.ORCID 0009-0004-5413-3287 Evangelos KokolesisHellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases, 11475 Athens, Greece.
Anastasia Antoniadou4th Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Chaidari, Greece.ORCID 0000-0003-0991-9198 Antonios Papadopoulos4th Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Chaidari, Greece.ORCID 0000-0003-4735-2620 Vasileios Papastamopoulos5th Department of Internal Medicine-Infectious Diseases Unit, Evangelismos General Hospital, 10676 Athens, Greece.ORCID 0000-0001-6293-0017 Apostolos BeloukasDepartment of Biomedical Sciences, University of West Attica, 12243 Athens, Greece.ORCID 0000-0001-5639-0528 Vana SypsaDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-9430-7614 Angelos HatzakisDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0001-8420-3830 Mina Psichogiou1st Department of Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-3000-8447 Funding
Gilead Not available now
6 · The paper itselfAbstract
People who inject drugs (PWIDs) remain underserved in HIV care. Evidence on rapid antiretroviral therapy (ART) for PWID is limited. We evaluated feasibility, effectiveness, safety, and patient-reported outcomes (PROs) for rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) supported by a peer navigation in Greece. This is a single-arm, multicenter pilot study including PWIDs (≥18 years) newly diagnosed or relinking after >3 months off ART. Participants started BIC/FTC/TAF on the same day or within 7 days and received peer navigation for 48 weeks. Co-primary endpoints were Week-24 virologic suppression (HIV-1 RNA < 50 copies/mL; FDA Snapshot) and grade 3-4 adverse events (AEs). Secondary endpoints included complete-case suppression at Weeks 24/48, CD4 recovery, retention, and PROs. Outcomes were compared with historical controls from the same centers. Thirty-seven participants were enrolled (83.8% male; median age 33.3 years). Median time to ART was 0 days (vs 78 in controls,
Indexed as
bictegravir/emtricitabine/tenofovir alafenamideintegrated care modelopioid agonist therapypatient-reported outcomespeer navigationpeople who inject drugsrapid ART initiationretention in care
Identifiers
PMID41471901
PMCPMC12735862
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390